Free Newsletter
Biovail pays fine for kickbacks
Biovail must pay $25 million in criminal and civil fines after the company pled guilty to charges that it paid doctors thousands of dollars to prescribe it's blood pressure drug Cardizem LA. The New Jersey-based drugmaker will fork over $22.2 million for the charges and an additional $2.4 million civil penalty. Report
More stories about Biovail
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: